Unmaintained remission after discontinuation of kinase inhibitor treatment in chronic lymphocytic leukemia: an observational cohort
Egle, A; Jager, U; Skrabs, C; Durig, J; Nosslinger, T; Wanner, D; Steurer, M; Ringshausen, I; Melchardt, T; Greil, R; Ysebaert, L ONCOL RES TREAT. 2019; 42: 18-18.
Cardiovascular events are declining in men with HIV aged 50 years or older in Austria
Rappold, M; Kitchen, M; Rieger, A; Schmied, B; Ollinger, A; Egle, A; Wallner, E; Kanatschnig, M; Zoufaly, A; Ledergerber, B; Zangerle, R HIV MED. 2019; 20: 118-119.
Similar but different: Using combined phylogenies of Austria and Switzerland reveals differences in transmission patterns of the local HIV-1 epidemics
Kusejko, K; Battegay, M; Bernasconi, E; Boni, J; Calmy, A; Cavassini, M; Egle, A; Grabmeier-Pfistershammer, K; Haas, B; Klimkait, T; Ollinger, A; Perreau, M; Ramette, A; Flury, BB; Sarcletti, M; Scherrer, A; Schmid, P; Yerly, S; Zangerle, R; Gunthard, HF; Kouyos, RD HIV MED. 2019; 20: 29-29.
BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Bishop, M; Flinn, I; Borchmann, P; Jaeger, U; Westin, J; Hamad, N; Purtill, D; Greil, R; Thomas, S; Teshima, T; Harigae, H; Garcia, C; Barba, P; Deol, A; Shaughnessy, P; Gu, J; Andreola, G; Prieto, MM; Pacaud, L; Schuster, S J IMMUNOTHER CANCER. 2019; 7:
The hepatitis C continuum of care among HIV-infected individuals in Austria
Rappold, M; Gisinger, M; Chromy, D; Schmied, B; Ollinger, A; Wallner, E; Zoufaly, A; Egle, A; Kanatschnig, M; Zangerle, R HIV MED. 2019; 20: 193-193.
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.
Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroeder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Vohringer, M; Oellinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Linz, B; Bernhard, H; Schoen, MR; Greil, R; Smith-Machnow, V; Schmidtmann, I; Moehler, MH J CLIN ONCOL. 2019; 37(4):
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
Hammel, P; Berardi, R; Van Cutsem, E; Feliu, J; Greil, R; Wasan, HS; Metges, JP; Nygren, P; Osterlund, PJ; Parner, V; Seufferlein, T; Gupta, A; Salesse, S; Biswasbaldwin, N; Ibrahim, A; Youssoufian, H; El-Hariry, I; Hidalgo, M J CLIN ONCOL. 2019; 37(4):
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Rischin, D; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Zhang, YY; Jin, F; Gumuscu, B; Burtness, B J CLIN ONCOL. 2019; 37(15):
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
Foukakis, T; Papakonstantinou, A; Matikas, A; Bengtsson, NO; Malmstrom, P; Hedayati, E; Steger, GG; Untch, M; Hubbert, L; Johansson, H; Hellstrom, M; Gnant, M; Loibl, S; Greil, R; Moebus, V; Bergh, JCS J CLIN ONCOL. 2019; 37(15):
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma: Data of real-world utilization in Austria.
Kocher, F; Seeber, A; Weiss, L; Romeder, F; Szkandera, J; Kuhr, T; Kostner, S; Pichler, P; Jager, T; Greil, R; Brodowicz, T J CLIN ONCOL. 2019; 37(15):